Cristiane Carvalho, MD
Nephrology · South Miami, FLNPI 1396919635
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.2% of the total across 206 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 12.5% — the pattern of someone who eats at a lot of different presentations.
Across 206 payments — averaging $24.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$620
- Amgen$591
- Mallinckrodt Hospital Products Inc.$434
- Aurinia Pharma U.S., Inc.$334
- Calliditas Therapeutics US Inc.$312
- Vifor Pharma, Inc.$307
- plus $2K from 21 others
Across 50 payments — averaging $5164.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$237K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$21K
- CSL Behring$65
What the payments were for
- Food & beverage$4,66694%
- Education$2876%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 26 | $620 |
| Amgen(2 entities) | 27 | $591 |
| Mallinckrodt Hospital Products Inc. | 11 | $434 |
| Aurinia Pharma U.S., Inc. | 14 | $334 |
| Calliditas Therapeutics US Inc. | 10 | $312 |
| Vifor Pharma, Inc. | 15 | $307 |
| GSK | 8 | $268 |
| AstraZeneca | 13 | $248 |
| Akebia Therapeutics Inc | 12 | $245 |
| Ardelyx, Inc. | 11 | $217 |
| Travere Therapeutics, Inc. | 13 | $189 |
| Daiichi Sankyo Inc. | 8 | $167 |
| OPKO Pharmaceuticals, LLC | 7 | $158 |
| Bayer | 6 | $152 |
| Sanofi | 1 | $125 |
| Boehringer Ingelheim | 4 | $97 |
| Novo Nordisk | 4 | $83 |
| Fresenius USA Marketing, Inc. | 3 | $65 |
| Nxstage Medical, Inc. | 1 | $61 |
| Lilly USA, LLC | 2 | $50 |
| Novartis | 2 | $48 |
| Mallinckrodt Enterprises LLC | 2 | $48 |
| Ultragenyx Pharmaceutical Inc. | 2 | $39 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $27 |
| Cormedix Inc. | 1 | $26 |
| Scpharmaceuticals Inc. | 1 | $22 |
| Shire North American Group Inc | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DISEASE STATE$125
- TARPEYO$125
- BENLYSTA$122
How this compares
$4,953 in reported general payments places this provider in the 80th percentile of 756 nephrology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 168 | $181,968 |
| JardianceEmpagliflozin | 82 | $89,375 |
| VeltassaPatiromer Calcium Sorbitex | 37 | $39,143 |
| LokelmaSodium Zirconium Cyclosilicate | 59 | $31,437 |
| KerendiaFinerenone | 15 | $14,089 |
| Lanthanum Carbonate | 14 | $9,363 |
| DapagliflozinDapagliflozin Propanediol | 16 | $8,031 |
| Sevelamer Carbonate | 16 | $5,879 |
| ProcritEpoetin Alfa | 15 | $4,787 |
| Nifedipine ErNifedipine | 59 | $2,861 |
| Bumetanide | 84 | $2,479 |
| Doxazosin Mesylate | 73 | $1,494 |
| Hydralazine Hcl | 90 | $1,295 |
| Losartan Potassium | 110 | $1,035 |
| Allopurinol | 121 | $871 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $248 | $213,405227 claims |
| Boehringer IngelheimJardiance | $97 | $89,37582 claims |
| BayerKerendia | $152 | $14,08915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 756 nephrology providers in Florida.
Other nephrology in South Miami
- Marcos EsquenaziSouth Miami$87K
- Arvind MadanOrlando$943K
- John CopleyWeston$934K
- Jorge LarranagaKissimmee$825K
- Carlos BejarFort Lauderdale$530K
- Wayne KotzkerFort Lauderdale$472K
- Jason RothschildTemple Terrace$413K
- Daniel PatelDaytona Beach$227K
- Rafael Baez BonillaFort Lauderdale$175K
- Gabriel ContrerasMiami$133K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.